149 related articles for article (PubMed ID: 30120701)
21. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
22. Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy.
Grabinski JL; Smith LS; Chisholm GB; Drengler R; Rodriguez GI; Lang AS; Kalter SP; Garner AM; Fichtel LM; Hollsten J; Pollock BH; Kuhn JG
Breast Cancer Res Treat; 2006 Jan; 95(1):13-6. PubMed ID: 16317586
[TBL] [Abstract][Full Text] [Related]
23. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
[TBL] [Abstract][Full Text] [Related]
24. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
25. CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
Jansen LE; Teft WA; Rose RV; Lizotte DJ; Kim RB
Breast Cancer Res Treat; 2018 Oct; 171(3):701-708. PubMed ID: 29980881
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
27. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
28. Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.
Sanchez-Spitman AB; Swen JJ; Dezentjé VO; Moes DJAR; Gelderblom H; Guchelaar HJ
Sci Rep; 2021 Jan; 11(1):415. PubMed ID: 33432065
[TBL] [Abstract][Full Text] [Related]
29. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
Gjerde J; Geisler J; Lundgren S; Ekse D; Varhaug JE; Mellgren G; Steen VM; Lien EA
BMC Cancer; 2010 Jun; 10():313. PubMed ID: 20565970
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
31. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
32. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.
Welzen ME; Dezentjé VO; van Schaik RH; Colbers AP; Guchelaar HJ; van Erp NP; den Hartigh J; Burger DM; van Laarhoven HW
Ther Drug Monit; 2015 Aug; 37(4):501-7. PubMed ID: 26192892
[TBL] [Abstract][Full Text] [Related]
33. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.
Souwer ETD; Sanchez-Spitman A; Moes DJAR; Gelderblom H; Swen JJ; Portielje JEA; Guchelaar HJ; van Gelder T
Breast Cancer Res Treat; 2023 Jun; 199(3):471-478. PubMed ID: 37067610
[TBL] [Abstract][Full Text] [Related]
35. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
36. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
37. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
Sanchez-Spitman AB; Moes DAR; Swen JJ; Dezentjé VO; Lambrechts D; Neven P; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1141-1152. PubMed ID: 32468081
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
Safgren SL; Suman VJ; Kosel ML; Gilbert JA; Buhrow SA; Black JL; Northfelt DW; Modak AS; Rosen D; Ingle JN; Ames MM; Reid JM; Goetz MP
Pharmacogenet Genomics; 2015 Apr; 25(4):157-63. PubMed ID: 25714002
[TBL] [Abstract][Full Text] [Related]
39. Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients.
Ximenez JP; Lanchote VL; Bello MA; Iocken FHS; Obadia RCM; de Sousa VP; Suarez-Kurtz G
Basic Clin Pharmacol Toxicol; 2020 May; 126(5):432-436. PubMed ID: 31758654
[TBL] [Abstract][Full Text] [Related]
40. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
